Aoyama R, Waga S, Ohnishi A, Izumi Y
Jpn J Antibiot. 1983 Apr;36(4):736-8.
T-1982 (cefbuperazone) is a newly developed cephamycin. Clinical studies on this drug were carried out and the results were as follows: Eighteen patients (pneumonia 13, purulent tonsillitis 1, acute bronchitis 1, cellulitis 1, urinary tract infection 2) were treated intravenously with daily 27.4-100.2 mg/kg of T-1982 in 3-4 divided dose for 3-6.7 days. The overall efficacy rate was 94.4%. No adverse reactions were observed. Abnormal laboratory data noted were liver dysfunction in 1 case (4.8%), eosinophilia in 2 cases (9.5%), and anemia in 1 case (4.8%).
T-1982（头孢布宗）是一种新开发的头孢霉素。对该药物进行了临床研究，结果如下：18例患者（肺炎13例、化脓性扁桃体炎1例、急性支气管炎1例、蜂窝织炎1例、尿路感染2例）静脉注射T-1982，剂量为每日27.4 - 100.2mg/kg，分3 - 4次给药，疗程为3 - 6.7天。总有效率为94.4%。未观察到不良反应。所记录的实验室异常数据为1例肝功能障碍（4.8%）、2例嗜酸性粒细胞增多（9.5%）和1例贫血（4.8%）。
